Development, anti-proliferative activity, multi-target kinase inhibition against CHK1, PIM1, and CDK-2, and computational insights of new thiazole-based hybrids
Key Points
The research aims to develop thiazole-based hybrids with multi-target kinase inhibition.
Targeting CHK1, PIM1, and CDK-2 in the design of new thiazole-based hybrids.
Evaluation of anti-proliferative activity in cancer models.
Computational analysis for insights on hybrid interactions.
Successful development of thiazole-based hybrids with significant anti-proliferative activity.
Inhibition of PIM1 identified as a key mechanism for cancer treatment.
Computational insights highlight structural effectiveness of hybrids.
Abstract
In the current medical landscape, multi-targeting by a single small molecule is recognized as an effective strategy in the fight against cancer.
Development, anti-proliferative activity, multi-target kinase inhibition against CHK1, PIM1, and CDK-2, and computational insights of new thiazole-based hybrids | Synapse